Pay in 4 interest-free payments of $7.11 Learn more
Ships within 48 hours · Estimated delivery Nov 13 - Nov 18
Always read the concentration on the new label and redo the conversion
The SELECT trial (Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity), a phase 3 study involving 17,604 adults with overweight or obesity and pre-existing CVD but no diabetes, revealed that once-weekly subcutaneous semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events by 20% compared with placebo over a mean follow-up of 39.8 months, including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke [48]
Journal of Clinical & Experimental Dermatology Research, 06(03)
Some patients may maintain treatment at 1.7 mg if the 2.4 mg dose is not tolerated
Alarmingly, 60% of Chinese manufacturers importing "semaglutide" for use in compounding or further manufacture are not even permitted to distribute that API in China for use in human drugs
US$ 29.59
US$ 22.98
US$ 27.93
